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of prescriptions, hospitalizations, visits and diagnostic examina-
tions in FVG. Direct medical costs were quantiﬁed in the per-
spective of the RHS and are expressed in Euro 2005. RESULTS:
We enrolled 2122 patients with incident CHF (mean age 78 ±
11 y.o.), 55.3% were women. The average cost person/year was
€5896, 54; 80% attributable to hospitalisations, 13.7% to drugs,
6.3% to other medical costs. A total of 1320 (62.2%) patients
died during the follow-up period. Mortality was higher in male
(p < 0.0001) and older subjects (p < 0.0001). CONLUSIONS:
CHF imposes a huge economic burden on NHS and society
because of the large number of hospitalisation and the high rate
of mortality after the ﬁrst event. Future investigations will be
conducted to asses the relationships between comorbidity, costs,
drug therapy and survival.
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OBJECTIVE: SOJA is a structured approach to the selection of
drugs for formulary inclusion. The aim of this study was to use
a modiﬁed SOJA approach in the selection of ACEI products for
use within a health board in Northern Ireland. METHODS: The
modiﬁed SOJA approach involved three phases in sequence: an
evidence based pharmacotherapeutic evaluation of all available
ACEI drug entities, a separate safety / risk assessment analysis
of products containing agents which exceeded the pharma-
cotherapeutic threshold and ﬁnally a budgetary impact analysis.
A comprehensive literature review and expert panel judgment,
informed selection of criteria (and their relative weighting) for
the pharmacotherapeutic evaluation. The resultant criteria /
scoring system was circulated (in questionnaire format) to pre-
scribers and stakeholders for comment. Based on statistical
analysis of the latter survey results, the ﬁnal scoring system was
developed. Drug entities which exceeded the evidence threshold
score were entered into a tendering process with pharmaceutical
suppliers. Products submitted as a result of the tendering process
were sequentially entered into the second and third phases of the
modiﬁed SOJA process (safety / risk assessment; budgetary
impact analysis). RESULTS: Five drug entities (from the 11 cur-
rently available in the UK) exceeded the evidence threshold and
22 from 26 submitted product lines, containing these drug enti-
ties, satisﬁed the safety evaluation / risk assessment criteria.
Three product lines, each containing a different drug entity, were
selected for formulary inclusion as a result of the budgetary
impact analysis. The estimated annual cost savings for ACEIs as
a result of this selection (based on estimated annual usage in
Deﬁned Daily Doses) in this health board was 41%. CONCLU-
SION: The modiﬁed SOJA approach has a signiﬁcant contribu-
tion to make in containing ACEI costs while retaining the same
level of patient care.
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OBJECTIVE: Risk assessment is important in determining the
management of patients with suspected or conﬁrmed coronary
artery disease (CAD). However, evidence supporting the clinical
impact of contrast echocardiography (CE) in this sphere is not
well known. The objective was to review and summarise the clin-
ical data for licensed and investigational applications of CE in
CAD, using systematic review methodology. METHODS: Full
publications of clinical studies of selected contrast agents were
identiﬁed through searches of electronic literature databases and
application of predeﬁned inclusion criteria. Studies were cate-
gorised and key data were extracted and tabulated for analysis.
No statistical pooling of data was undertaken due to study het-
erogeneity. RESULTS: 2275 abstracts were screened. 61 studies
met inclusion criteria and were categorised as follows: effective-
ness in image enhancement (23 studies); accuracy in the diagno-
sis of CAD, using coronary angiography as the diagnostic gold
standard (23 studies); myocardial viability assessment (16
studies); prognostic accuracy (2 studies). Using second genera-
tion contrast agents, diagnostic images were obtained in 48–98%
(median = 74%) of patients with suboptimal un-enhanced
images and several studies reported improved intra- and inter-
operator reproducibility. Reported sensitivities and speciﬁcities
for CAD diagnosis ranged from 41–100% (median = 86%) and
44–100% (median = 81%). Two studies reported that informa-
tion gained from myocardial contrast echocardiography (MCE)
provided incremental diagnostic value to that from left ventric-
ular function (LVF) assessment alone. Reported sensitivities 
and speciﬁcities of myocardial viability assessment by MCE 
for predicting LVF recovery ranged from 50–96% (median =
74%) and 44–96% (median = 83%). CONCLUSIONS: The
body of evidence suggests that effective use of contrast agents in
echocardiography extends beyond the licensed use in patients
with suboptimal baseline images. MCE is effective in the assess-
ment of myocardial perfusion in the diagnosis of CAD and the
detection of myocardial viability. Interpretation is limited by the
size of studies, lack of long-term outcomes and potential refer-
ral bias.
PCV30
CLOPIDOGREL LOADING DOSE AND CARDIOVASCULAR
OUTCOMES IN ACUTE CORONARY SYNDROME 
PATIENTS WHO UNDERGO PERCUTANEOUS 
CORONARY INTERVENTION
Wang C1, He J1, Bae JP2, McCollam PL2, Grifﬁn BT1
1Solucient, Inc, Berkeley Heights, NJ, USA; 2Eli Lilly and Company,
Indianapolis, IN, USA
OBJECTIVES: The 2002 AHA/ACC guideline recommends
acute coronary syndrome patients who undergo percutaneous
coronary intervention (ASC-PCI) be given 300mg loading dose
(LD) of clopidogrel, but higher LD has emerged in practice. A
recent trial involving 255 patients found 600mg of clopidogrel
had better outcomes than 300mg (Patti et al, 2005). The current
study investigates whether patients treated with higher clopido-
grel LD experience better outcomes in the usual care setting.
METHODS: We followed 6,282 ACS-PCI patients in a national
hospital database with time-stamp information (1/2003–9/2004)
for 60 days upon discharge. Using the time-stamp, LD was mea-
sured as total dose within 24-hour window of peri-PCI proce-
dure, and myocardial infarction (MI) was captured from
post-procedure lab tests. Patients receiving >300mg are grouped
into high LD (HLD) (nH = 1465) and £300mg, the low LD
group (LLD) (nL = 4152). Primary endpoints (i.e., death, stroke,
repeat revascularization, and MI) plus bleeding and re-admission
were monitored. Logistic regression tested effects of LD on
events with controls for risk. RESULTS: LD ranged from 75mg
to 1275mg. The HLD group did not experience better outcome.
While 28.49% of LLD experienced an event, the rate was
44.23% for the HLD (p < 0.0001). MI rate was higher for HLD
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at 42.18% compared to 25.91% of LLD (p < 0.0001). Bleeding,
readmission, and mortality were similar (p = NS). Risk-adjusted
logistic regression also found no evidence for better outcome 
in patients given HLD of clopidogrel. CONCLUSIONS: Using
time-stamp data, this large study retrospectively investigated
effects of HLD clopidogrel in usual care setting. Patients receiv-
ing HLD did not experience better outcome. If providers tend to
select HLD to treat high-risk patients in practice, an underlying
dose-outcome bias would exist in the data. It is unclear how
much of the bias is mitigated by higher dosing in the usual care
setting. More research is needed.
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OBJECTIVE: To review the existing evidence of the economic
impact of contrast echocardiography (CE) in the diagnosis and
management of patients with suspected or known coronary
artery disease (CAD). METHODS: A systematic search was
undertaken to identify studies that provided empirical evidence
of the cost-effectiveness of CE relative to an alternative diag-
nostic modality. Findings and study methodologies were
reviewed and suggestions for further research were offered.
RESULTS: Six studies were identiﬁed, including one conference
abstract and one unpublished study. In four studies of patients
with sub-optimal un-enhanced echocardiogaphic images, CE was
reported to reduce the average cost to obtain a diagnosis by
17–64% compared with a second-line nuclear imaging (SPECT)
test. However, these studies did not include the impact of poten-
tial differences in diagnostic accuracy between tests. A ﬁfth study
reported that compared with trans-oesophageal echocardiogra-
phy CE resulted in similar yield of accurate diagnoses at a sub-
stantial reduction in costs for determination of regional and
global ventricular function in ‘technically difﬁcult to image’
patients. In a sixth study in patients with an intermediate risk
for CAD, the average cost to identify CAD was lowest when
SPECT Tc-99m or CE ($267 and $355 per case detected, respec-
tively) and highest when exercise electrocardiography ($1320 per
case detected) was used as the ﬁrst-line test. CONCLUSIONS:
The results support the cost-effectiveness of CE compared with
nuclear imaging in patients with a sub-optimal un-enhanced
image, and potentially in other patient sub-groups such as those
with an intermediate risk of CAD. However, more comprehen-
sive economic analyses incorporating diagnostic accuracy and its
implications for patient management are required before these
results can be considered conclusive. More research is also
needed to assess the economic impact of myocardial contrast
echocardiography (MCE) in its wider applications in the man-
agement of CAD patients, such as the assessment of myocardial
viability.
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OBJECTIVES: The efﬁcacy of platelet inhibition with clopido-
grel for patients (pts) with non-ST-elevation acute coronary syn-
dromes was demonstrated in CURE and PCI-CURE trials. The
purpose of present analysis is to estimate the long-term cost-
effectiveness of clopidogrel in Poland, using clinical outcomes
and resource utilization from CURE and in PCI-CURE.
METHODS: Costs of hospitalizations and studied drugs were
calculated based on resource utilization collected in case report
form for all pts in CURE (clopidogrel, n = 6259, placebo, n =
6303) and in the subgroup of PCI-CURE pts (clopidogrel/n =
1313, placebo/n = 1345). Comedications were not included in
the economic analyses as drug utilization was similar in clopi-
dogrel and placebo group. Unit costs were calculated using drugs
retail prices and medical procedures tariffs contracted by
National Health Found. Because of lack of sufﬁcient Polish epi-
demiological data two different sources (Framingham and
Saskatchewan databases) were used to evaluate the lost life
expectancy associated with death, MI and stroke. A discount rate
of 3% was applied. Results are expressed in cost per Life Year
Saved. RESULTS: Total cost per pt was higher in the clopidogrel
arm for CURE and PCI-CURE (+€463 and +€454) respectively.
The estimated number of LYS with clopidogrel for CURE pts
was 69.9 per 1000pts treated using Framingham and 68.2 using
Saskatchewan data. Corresponding values for PCI-CURE were
69.8 per 1000 patients with Framingham and 88.5 with
Saskatchewan data. The cost per LYS for clopidogrel versus
placebo for CURE pts was €6624 with Framingham and €6789
with Saskatchewan database. For PCI-CURE pts these ﬁgures
were €6504 and €5130 respectively. CONCLUSION: Based on
the clinical ﬁndings of CURE and PCI-CURE trials clopidogrel
appears to be cost-effective in Poland. Although results obtained
from two different sources of survival data are consistent, the
interpretation of present ﬁndings requires further adjustment to
Polish epidemiological settings.
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OBJECTIVES: Low-dose Aspirin is standard care in patients
with cardiovascular disease (CVD). In primary prevention the
use of Aspirin is not fully established although meta-analyses and
guidelines support its use in persons at increased CVD risk. This
study assessed the health economic consequences of the use of
low-dose Aspirin in the primary prevention of CVD in the UK,
Germany, Spain and Italy. METHODS: Based on results reported
in two meta-analyses, a Markov model was developed to predict
the cost-effectiveness of Aspirin in the primary prevention of
CVD. Different time horizons (1 to 10 years), 1-year cycles and
direct costs from the health care payer’s perspective (2003) were
used. Effects were expressed in Life-Years (LY) and QALY. Utility
data (TTO) were obtained from published data. Country speciﬁc
discounting was applied. RESULTS: For patients with an annual
risk of coronary heart disease (CHD) of 1.5%, the model results
in average savings with low-dose aspirin after 10 years of €201
[95%CI €81–€331], €281 [95%CI €141–€422], €797 [95%CI
€301–€1331] and €427 [95%CI €122–731] per patient in the
UK, Germany, Spain and Italy, respectively. Although the savings
in the ﬁrst year are modest (on average €10-€20), from the
second year on they are signiﬁcant in all countries. Sensitivity
analysis showed the results robustness. The number of LY and
QALY gained with aspirin were respectively 0.2 and 0.4 years 
in the four countries. Monte Carlo analysis showed aspirin-
